Research progress in promoting synaptic regeneration in neurodegenerative diseasesy

Shengchun LOU, Chengye ZHAO, Suqin ZHOU, Shixin LI

Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2026, Vol. 9 ›› Issue (5) : 349-356.

PDF(859 KB)
Home Journals Chinese Journal of Alzheimer's Disease and Related Disorders
Chinese Journal of Alzheimer's Disease and Related Disorders

Abbreviation (ISO4): Chinese Journal of Alzheimer's Disease and Related Disorders      Editor in chief: Jun WANG

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(859 KB)
Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2026, Vol. 9 ›› Issue (5) : 349-356. DOI: 10.3969/j.issn.2096-5516.2026.05.011
Reviews

Research progress in promoting synaptic regeneration in neurodegenerative diseasesy

Author information +
History +

Abstract

Synaptic dysfunction and loss are early core pathological events in neurodegenerative diseases. This article systematically reviews the cellular and molecular mechanisms underlying synaptic dysfunction, identifying the dysregulation of neurons, astrocytes, and microglia as the core cellular mechanism. Furthermore, it highlights the intertwined pathological networks of neuroinflammation, metabolic disorder, and protein homeostasis imbalance, which collectively drive the vicious cycle of synaptic dysfunction. Additionally, the article introduces the synaptic regeneration regulatory system centered around brain-derived neurotrophic factor and summarizes emerging therapeutic strategies such as small molecule drugs targeting multiple pathways, cell and gene therapies, non-coding RNA regulation, and non-pharmacological interventions. Furthermore, it discusses the application of cutting-edge technologies such as synaptic density PET imaging, induced pluripotent stem cells (iPSC), and brain organoids in synaptic regeneration research. In the future, the treatment of neurodegenerative diseases may shift from single-target approaches to multidimensional interventions, integrating various therapies and lifestyle adjustments to achieve a leap from delaying disease progression to functional restoration.

Key words

Neurodegenerative diseases / Synapse regeneration / Pathological mechanisms / Therapeutic strategies

Cite this article

Download Citations
Shengchun LOU , Chengye ZHAO , Suqin ZHOU , et al. Research progress in promoting synaptic regeneration in neurodegenerative diseasesy[J]. Chinese Journal of Alzheimer's Disease and Related Disorders. 2026, 9(5): 349-356 https://doi.org/10.3969/j.issn.2096-5516.2026.05.011

References

[1]
Zota I, Calogeropoulou T, Chanoumidou K, et al. Synthetic microneurotrophins: Neurotrophin receptors for therapeutics of neurodegenerative diseases[J]. Br J Pharmacol, 2025, 182(19):4466-4489.
[2]
Blivet G, Touchon B, Cavadore H, et al. Brain photobiomodulation: A potential treatment in Alzheimer's and Parkinson's diseases[J]. J Prev Alzheimers Dis, 2025, 12(7):100185.
[3]
Hall B, Amin N, Veeranna, et al. A retrospective tribute to Dr. harish pant (1938-2023) and his seminal work on cyclin dependent kinase 5[J]. Neurochem Res, 2024, 49(12):3181-3186.
[4]
Bhatt A, Bhardwaj H, Srivastava P. Mesenchymal stem cell therapy for Alzheimer's disease: A novel therapeutic approach for neurodegenerative diseases[J]. Neuroscience, 2024, 555:52-68.
[5]
Eichler A, Kruse P, Schob C, et al. Synaptic transmission in supragranular layers of the human cortex - comparative review of structure, function, and plasticity[J]. Front Synaptic Neurosci, 2025, 17:1724377.
[6]
Terry R D, Masliah E, Salmon D P, et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment[J]. Ann Neurol, 1991, 30(4):572-580.
[7]
Dejanovic B, Sheng M, Hanson J E. Targeting synapse function and loss for treatment of neurodegenerative diseases[J]. Nat Rev Drug Discov, 2024, 23(1):23-42.
[8]
Shen W, Zhai S, Surmeier D J. Striatal synaptic adaptations in Parkinson's disease[J]. Neurobiol Dis, 2022, 167:105686.
[9]
Cattaneo C, Jost W H. Pain in Parkinson's disease: Pathophysiology, classification and treatment[J]. J Integr Neurosci, 2023, 22(5):132.
[10]
Barry J, Bui M T N, Levine M S, et al. Synaptic pathology in Huntington's disease: Beyond the corticostriatal pathway[J]. Neurobiol Dis, 2022, 162:105574.
[11]
Chmiel J, Nadobnik J, Smerdel S, et al. Neural correlates of Huntington's disease based on electroencephalography (EEG): A mechanistic review and discussion of excitation and inhibition (E/I) imbalance[J]. J Clin Med, 2025, 14(14):5010.
[12]
Hagena H, Manahan-Vaughan D. Interplay of hippocampal long-term potentiation and long-term depression in enabling memory representations[J]. Philos Trans R Soc Lond B Biol Sci, 2024, 379(1906):20230229.
[13]
Chambel S S, Cruz C D. Axonal growth inhibitors and their receptors in spinal cord injury: From biology to clinical translation[J]. Neural Regen Res, 2023, 18(12):2573-2581.
[14]
Patel J C, Shukla M, Shukla M. Cellular and molecular interactions in CNS injury: The role of immune cells and inflammatory responses in damage and repair[J]. Cells, 2025, 14(12):918.
[15]
Liu F, Bai Q, Tang W, et al. Antioxidants in neuropsychiatric disorder prevention: Neuroprotection, synaptic regulation, microglia modulation, and neurotrophic effects[J]. Front Neurosci, 2024, 18:1505153.
[16]
Kokkali M, Karali K, Thanou E, et al. Multimodal beneficial effects of BNN27, a nerve growth factor synthetic mimetic, in the 5xFAD mouse model of Alzheimer's disease[J]. Mol Psychiatry, 2025, 30(6):2265-2283.
[17]
Choi G E, Park J Y, Park M R, et al. Restoration of Miro1's N-terminal GTPase function alleviates prenatal stress-induced mitochondrial fission via Drp1 modulation[J]. Cell Commun Signal, 2025, 23(1):166.
[18]
Neuman S D, Thakur R S, Gratz S J, et al. Neurodegenerative and neurodevelopmental roles for bulk lipid transporters VPS13A and BLTP2[J]. Mov Disord, 2025, 40(7):1356-1368.
[19]
Wennagel D, Braz B Y, Capizzi M, et al. Huntingtin coordinates dendritic spine morphology and function through cofilin-mediated control of the actin cytoskeleton[J]. Cell Rep, 2022, 40(9):111261.
[20]
Ma H, Zhao H, Feng X, et al. The interaction between resilience framework and neuron-astrocyte-synapse dynamics in AD[J]. Front Aging Neurosci, 2025, 17:1644532.
[21]
Munoz De Leon-Lopez C A, Navarro-Lobato I, Khan Z U. The role of astrocytes in synaptic dysfunction and memory deficits in Alzheimer's disease[J]. Biomolecules, 2025, 15(7):910.
[22]
Parsai L, Chali F, Subashi E, et al. Astrocyte-neuron combined targeting for CYP46A1 gene therapy in Huntington's disease[J]. Acta Neuropathol Commun, 2025, 13(1):184.
[23]
Schroder S, Fuchs U, Gisa V, et al. PRDM16-DT is a novel lncRNA that regulates astrocyte function in Alzheimer's disease[J]. Acta Neuropathol, 2024, 148(1):32.
[24]
Wen X, Cao W, Ding H, et al. Extracellular vesicles derived from FGF2-primed astrocytes against mitochondrial and synaptic toxicities in Parkinson's disease[J]. Int J Nanomedicine, 2025, 20:4627-4644.
[25]
Pramanik S, Devi M H, Chakrabarty S, et al. Microglia signaling in health and disease - implications in sex-specific brain development and plasticity[J]. Neurosci Biobehav Rev, 2024, 165:105834.
[26]
Ball J B, Green-Fulgham S M, Watkins L R. Mechanisms of microglia-mediated synapse turnover and synaptogenesis[J]. Prog Neurobiol, 2022, 218:102336.
[27]
Golkar A, Razazpour F, Dalfardi M, et al. Molecular mechanisms underlying obesity-induced memory dysfunction: A comprehensive narrative review[J]. Physiol Behav, 2026, 303:115119.
[28]
Astillero-Lopez V, Villar-Conde S, Gonzalez-Rodriguez M, et al. Proteomic analysis identifies HSP90AA1, PTK2B, and ANXA2 in the human entorhinal cortex in Alzheimer's disease: Potential role in synaptic homeostasis and Abeta pathology through microglial and astroglial cells[J]. Brain Pathol, 2024, 34(4):e13235.
[29]
Casaletto K B, Lindbergh C A, VandeBunte A, et al. Microglial correlates of late life physical activity: Relationship with synaptic and cognitive aging in older adults[J]. J Neurosci, 2022, 42(2):288-298.
[30]
Dolgacheva L P, Zinchenko V P, Nadeev A D, et al. Serotonergic regulation in Alzheimer's disease[J]. Int J Mol Sci, 2025, 26(11):5218.
[31]
Taddei R N, Perbet R, Mate De Gerando A, et al. Tau oligomer-containing synapse elimination by microglia and astrocytes in Alzheimer disease[J]. JAMA Neurol, 2023, 80(11):1209-1221.
[32]
Fang K, Pishva E, Piers T, et al. Amyloid-beta can activate JNK signalling via WNT5A-ROR2 to reduce synapse formation in Alzheimer's disease[J]. J Cell Sci, 2025, 138(3):JCS263526.
[33]
Withana M, Bradfield L, Jansen M I, et al. PAC1 receptor knockout mice reveal critical links between ER stress, myelin homeostasis, and neurodegeneration[J]. Int J Mol Sci, 2025, 26(17):8668.
[34]
Herrera-Fernandez V, Fanlo-Ucar H, Gohl P, et al. Predicting cellular adaptation proteins dependent on eIF2alpha regulation under stress conditions: Physiological and pathophysiological implications in neuronal function[J]. Comput Struct Biotechnol J, 2025, 27:3127-3136.
[35]
Lior N, Chen D, Dan F, et al. The connection between autophagy and Alzheimer's disease[J]. Inflamm Res, 2025, 74(1):148.
[36]
Chen D, Jiang Y, Ge F, et al. High-frequency repetitive transcranial magnetic stimulation upregulates BDNF expression and promotes synaptogenesis in mouse models of Parkinson's disease[J]. Neuroscience, 2025, 579:129-143.
[37]
Gu Y, Pope A, Smith C, et al. BDNF and TRiC-inspired reagent rescue cortical synaptic deficits in a mouse model of Huntington's disease[J]. Neurobiol Dis, 2024, 195:106502.
[38]
She L, Tang H, Zeng Y, et al. Ginsenoside RK3 promotes neurogenesis in Alzheimer's disease through activation of the CREB/BDNF pathway[J]. J Ethnopharmacol, 2024, 321:117462.
[39]
Gao A X, Xia T C, Lin L S, et al. The neurotrophic activities of brain-derived neurotrophic factor are potentiated by binding with apigenin, a common flavone in vegetables, in stimulating the receptor signaling[J]. CNS Neurosci Ther, 2023, 29(10):2787-2799.
[40]
Cai C, Wang L, Li S, et al. Ras inhibitor lonafarnib rescues structural and functional impairments of synapses of abeta(1-42) mice via alpha7nAChR-Dependent BDNF upregulation[J]. J Neurosci, 2022, 42(31):6090-6107.
[41]
Wang C, Chen T, Li G, et al. Simvastatin prevents beta-amyloid(25-35)-impaired neurogenesis in hippocampal dentate gyrus through alpha7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate[J]. Neuropharmacology, 2015, 97:122-132.
[42]
Xiao L, Sharma P, Yang X, et al. Neurotrophic factor-alpha1/carboxypeptidase E regulates critical protein networks to rescue neurodegeneration, defective synaptogenesis and impaired autophagy in Alzheimer's disease mice[J]. Transl Neurodegener, 2025, 14(1):59.
[43]
Fan F, Liu L, Guo M, et al. Neurotrophic factor-alpha1/carboxypeptidase E controls progression and reversal of Alzheimer's disease pathogenesis in mice[J]. Theranostics, 2025, 15(6):2279-2292.
[44]
Colin-Martinez E, Arias C. Intracerebral administration of Wnt7a improves memory performance and increases synaptophysin expression in the 3xTg-AD mouse model[J]. Neurosci Lett, 2025, 865(13):138336.
[45]
Ma H, Chang Z, Sun H, et al. A novel Dual GLP-1/CCK receptor agonist improves cognitive performance and synaptogenesis in the 5 x FAD Alzheimer mouse model[J]. Mol Neurobiol, 2025, 62(9):11920-11934.
[46]
Zago A M, Carvalho F B, Rahmeier F L, et al. Exendin-4 prevents memory loss and neuronal death in rats with sporadic Alzheimer-like disease[J]. Mol Neurobiol, 2024, 61(5):2631-2652.
[47]
Tu H, Chao M, Lee C, et al. Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-beta formation[J]. J Enzyme Inhib Med Chem, 2024, 39(1):2418470.
[48]
Zhang C, Wang J, Wang W. Wnt signaling in synaptogenesis of Alzheimer's disease[J]. Ibrain, 2023, 9(3):316-325.
[49]
de Souza P C, Warren Bezerra T P, de Oliveira I L R, et al. MicroRNAs in neuroplasticity: A comprehensive review of mechanisms and therapeutic strategies for neurodegenerative diseases[J]. Neuroscience, 2025, 585:97-106.
[50]
Islam M A, Sultana O F, Bandari M, et al. MicroRNA-455-3P as a peripheral biomarker and therapeutic target for mild cognitive impairment and Alzheimer's disease[J]. Ageing Res Rev, 2024, 100:102459.
[51]
Ghasemi A, Qaffaripour Z, Tourani M, et al. The relationship between long non-coding RNAs and Wnt/beta-catenin signaling pathway in the pathogenesis of Alzheimer's disease[J]. Exp Neurol, 2023, 366:114434.
[52]
Verwaerde P, Defert O. AZP2006 (Ezeprogind(R)): A promising new drug candidate in the battle against neurodegenerative diseases[J]. Chem Med Chem, 2025, 20(10):e202400891.
[53]
Ding N, Wang P, Fang Y, et al. Luteolin attenuates trimethyltin chloride-induced hippocampal neurotoxicity through SIRT3/NRF2/HO-1 activation[J]. Neuropharmacology, 2025, 274:110461.
[54]
Zhang J, Du X, Li X, et al. Hypoxia, psychedelics, and terminal lucidity: A perspective on neuroplasticity and neuropsychiatric disorders[J]. ACS Pharmacol Transl Sci, 2025, 8(9):2848-2854.
[55]
Penzenstadler L, Baudois S, Lingenberg A, et al. Treatment with psychedelics : Potential benefits in Parkinson's disease[J]. Rev Med Suisse, 2025, 21(915):849-852.
[56]
Kozlowska U, Nichols C, Wiatr K, et al. From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders[J]. J Neurochem, 2022, 162(1):89-108.
[57]
Alidoust L, Akhoondian M, Atefi A H, et al. Stem cell-conditioned medium is a promising treatment for Alzheimer's disease[J]. Behav Brain Res, 2023, 452:114543.
[58]
Qin C, Bai L, Li Y, et al. The functional mechanism of bone marrow-derived mesenchymal stem cells in the treatment of animal models with Alzheimer's disease: Crosstalk between autophagy and apoptosis[J]. Stem Cell Res Ther, 2022, 13(1):90.
[59]
Choi Y, Shin S, Son H J, et al. Identification of potential biomarkers related to mesenchymal stem cell response in patients with Alzheimer's disease[J]. Stem Cell Res Ther, 2023, 14(1):178.
[60]
Ma M, Jing G, Tian Y, et al. Irisin: Emerging therapeutic targets for cognitive impairment-related diseases[J]. Expert Rev Mol Med, 2025, 27:e23.
[61]
Ciumarnean L, Sarb O, Draghici N, et al. Obesity control and supplementary nutraceuticals as cofactors of brain plasticity in multiple sclerosis populations[J]. Int J Mol Sci, 2024, 25(20).
[62]
Alizadeh Pahlavani H. Possible role of exercise therapy on depression: Effector neurotransmitters as key players[J]. Behav Brain Res, 2024, 459:114791.
[63]
Feeney S P, McCarthy J M, Petruconis C R, et al. Sleep loss is a metabolic disorder[J]. Sci Signal, 2025, 18(881):eadp9358.

Footnotes

利益冲突声明 所有作者均不存在利益冲突。

PDF(859 KB)

Accesses

Citation

Detail

Sections
Recommended

/

〈 〉